Rhodes Jason P 4
4 · Dyne Therapeutics, Inc. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
Dyne Therapeutics (DYN) Director Jason P. Rhodes Sells Shares
What Happened
- Jason P. Rhodes, a director of Dyne Therapeutics (DYN), disposed of a total of 777,451 shares in open-market sales on July 6–7, 2026, generating aggregate proceeds of approximately $17,858,491. Individual reported lots ranged from 5,000 to 253,039 shares at weighted-average prices between $22.79 and $23.62 (per the filing); the filing includes detailed price ranges for the multiple trade executions.
- These were sales (not purchases), and the filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2026 (Footnote F1).
Key Details
- Transaction dates: July 6, 2026 and July 7, 2026.
- Reported lots/weighted-average prices and proceeds (examples): 253,039 @ $22.79 = $5,766,759; 127,182 @ $22.79 = $2,898,478; 100,019 @ $22.79 = $2,279,433; additional lots at $23.17–$23.62; total ~777,451 shares for ~$17.86M.
- Pricing notes: the filing reports weighted-average prices and supplies execution ranges (see footnotes F2, F6–F8) — full per-price breakdown is available from the issuer/SEC upon request.
- Holdings after the transaction: the provided excerpt does not state Rhodes’s remaining beneficial ownership; several lots are reported as held by Atlas Venture funds (Footnotes F3–F5, F9), and Rhodes disclaims Section 16 beneficial ownership of those fund-held shares except to the extent of any pecuniary interest.
- Timeliness: Form 4 was filed July 8, 2026 for transactions on July 6–7, 2026 — this appears to be a timely filing (Form 4 is generally due within two business days).
Context
- These sales were executed under a pre-established 10b5-1 plan, which is commonly used to schedule insider sales and reduces the implication that the sales were motivated by inside, short-term information. Sales are generally less informative than purchases for signaling insider confidence, and the presence of a 10b5-1 plan suggests routine, planned disposals.
- Many of the shares were held by venture funds affiliated with Atlas Venture; the filing’s footnotes clarify entity ownership and Rhodes’s disclaimer of beneficial ownership for those fund-held securities.
Insider Transaction Report
Form 4
Rhodes Jason P
Director
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-07-06$22.79/sh−253,039$5,766,759→ 4,223,448 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F4]2026-07-06$22.79/sh−127,182$2,898,478→ 1,217,537 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F5]2026-07-06$22.79/sh−100,019$2,279,433→ 875,912 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F3]2026-07-07$23.17/sh−124,379$2,881,861→ 4,099,069 total(indirect: See footnote) - Sale
Common Stock
[F1][F7][F3]2026-07-07$23.62/sh−29,587$698,845→ 4,069,482 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F4]2026-07-07$23.17/sh−62,543$1,449,121→ 1,154,994 total(indirect: See footnote) - Sale
Common Stock
[F1][F7][F4]2026-07-07$23.62/sh−14,844$350,615→ 1,140,150 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F5]2026-07-07$23.17/sh−49,193$1,139,802→ 826,719 total(indirect: See footnote) - Sale
Common Stock
[F1][F7][F5]2026-07-07$23.62/sh−11,665$275,527→ 815,054 total(indirect: See footnote) - Sale
Common Stock
[F8][F9]2026-07-07$23.61/sh−5,000$118,050→ 2,962 total(indirect: See footnote)
Footnotes (9)
- [F1]Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
- [F2]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8).
- [F3]The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.
- [F4]The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
- [F5]The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
- [F6]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4572 to $23.4553 inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.46 to $23.8628 inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $23.50 to $23.794 inclusive.
- [F9]The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.
Signature
/s/ Ommer Chohan, Attorney-in-Fact|2026-07-08